Effects of the angiotensin II receptor blocker losartan on the monocyte expression of biglycan in hypertensive patients

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 9, 2010, Pages 933-938

  Sardo, Maria A ^a   Mandraffino, Giuseppe ^a   Riggio, Stefania ^a   D'Ascola, Angela ^a   Alibrandi, Angela ^a   Saitta, Carlo ^a   Imbalzano, Egidio ^a   Castaldo, Maria ^a   Cinquegrani, Maurizio ^a   Saitta, Antonino ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

angiotensin II; arterial hypertension; AT1 receptor antagonists; biglycan; inflammation; monocytes

Indexed keywords

BIGLYCAN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; LOSARTAN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION;

ADULT; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIGLYCAN; BLOOD PRESSURE; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYPERTENSION; INTERLEUKIN-6; LOSARTAN; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956039944     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05407.x     Document Type: Article

References (48)

1. Iozzo R. The biology of the small leucine-rich proteoglycans: Functional network of interactive proteins. J. Biol. Chem. 1999 274 : 18843 18846.
2. Iozzo RV. Matrix proteoglycans: From molecular design to cellular function. Annu. Rev. Biochem. 1998 67 : 609 652.
3. Ameye L, Aria D, Jepsen K, Oldberg A, Xu T, Young MF. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J. 2002 16 : 673 680.
4. Xu T, Bianco P, Fisher LW et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 1998 20 : 78 82.
5. Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E, Hayashi M, Saruta T. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ. Res. 2004 94 : 1067 1074.
6. Schaefer L, Beck KF, Raslik I et al. Biglycan, a nitric oxide-regulated gene, affects adhesion, growth, and survival of mesangial cells. J. Biol. Chem. 2003 278 : 26227 26237.
7. Tufvesson E, Westergren-Thorsson G. Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett. 2002 530 : 124 128.
8. Moreno M, Muñoz R, Aroca F, Labarca M, Brandan E, Larraín J. Biglycan is a new extracellular component of the chordin-BMP4 signaling pathway. EMBO J. 2005 24 : 1397 1405.
9. Weber C, Sommer G, Michl P et al. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology 2001 121 : 657 667.
10. Tufvesson E, Westergren-Thorsson G. Biglycan and decorin induce morphological and cytoskeletal changes involving signalling by the small GTPases RhoA and Rac1 resulting in lung fibroblast migration. J. Cell Sci. 2003 116 : 4857 4864.
11. Sime PJ, Sarnstrand B, Xing Z, Graham F, Fisher L, Gauldie J. Adenovirus-mediated gene transfer of the proteoglycan biglycan induces fibroblastic responses in the lung. Chest 1997 111 (Suppl. 137S (Abstract).
12. Kikuchi A, Tomoyasu H, Kido I et al. Haemopoietic biglycan produced by brain cells stimulates growth of microglial cells. J. Neuroimmunol. 2000 106 : 78 86.
13. Santiago-Garcia J, Kodama T, Pitas RE. The class A scavenger receptor binds to proteoglycans and mediates adhesion of macrophages to the extracellular matrix. J. Biol. Chem. 2003 278 : 6942 6946.
14. Chieppa M, Bianchi G, Doni A et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J. Immunol. 2003 171 : 4552 4560.
15. Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 2005 115 : 2223 2233.
16. Babelova A, Moreth K, Tsalastra-Greul W et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 2009 284 : 24035 24048.
17. Sardo MA, Mandraffino G, Campo S et al. Biglycan expression in hypertensive subjects with normal or increased carotid intima-media wall thickness. Clin. Chim. Acta 2009 406 : 89 93.
18. Libby P. Inflammatory mechanisms: The molecular basis of inflammation and disease. Nutr. Rev. 2007 65 (Suppl. S140 6.
19. Packard RR, Libby P. Inflammation in atherosclerosis: From vascular biology to biomarker discovery and risk prediction. Clin. Chem. 2008 54 : 24 38.
20. Wang CH, Li SH, Weisel RD et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003 107 : 1783 1790.
21. Fleming I, Kohlstedt K, Busse R. The tissue renin-angiotensin system and intracellular signalling. Curr. Opin. Nephrol. Hypertens. 2006 15 : 8 13.
22. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J. Renin Angiotensin Aldosterone Syst. 2006 7 : 3 14.
23. Schulman IH, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: Role in atherosclerosis and hypertension. J. Hypertens. 2006 24 (Suppl. S45 50.
24. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 2007 21 : 20 7.
25. Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxidative stress. Curr. Opin. Cardiol. 2007 22 : 311 315.
26. Sano M, Fukuda K, Sato T et al. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ. Res. 2001 89 : 661 669.
27. Kranzhöfer R, Browatzki M, Schmidt J, Kübler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem. Biophys. Res. Commun. 1999 257 : 826 828.
28. Tiede K, Stöter K, Petrik C et al. Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGF-beta in vitro. Cardiovasc. Res. 2003 60 : 538 546.
29. Figueroa JE, Vijayagopal P. Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis 2002 162 : 261 268.
30. Huang F, Thompson JC, Wilson PG, Aung HH, Rutledge JC, Tannock LR. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J. Lipid Res. 2008 49 : 521 530.
31. 1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br. J. Pharmacol. 2007 152 : 1042 1048.
32. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J. Am. Coll. Cardiol. 2001 37 : 440 444.
33. Koh KK, Ahn JY, Han SH et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J. Am. Coll. Cardiol. 2003 42 : 905 910.
34. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat. Protoc. 2006 1 : 1559 1582.
35. Dörffel Y, Lätsch C, Stuhlmüller B et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999 34 : 113 117.
36. Dörffel Y, Wallukat G, Bochnig N et al. Agonistic AT(1) receptor autoantibodies and monocyte stimulation in hypertensive patients. Am. J. Hypertens. 2003 16 : 827 833.
37. 1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 2004 119 : 343 354.
38. 1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Mol. Cell. Endocrinol. 2009 302 : 237 243.
39. Fortuño A, Bidegain J, Robador PA et al. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: Potential clinical implications in hypertension. Hypertension 2009 54 : 744 750.
40. 1 receptor/nuclear factor-kappaB pathway in brain microvascular endothelial cells. Life Sci. 2006 78 : 1293 1298.
41. 1 receptor blockade. Am. J. Cardiovasc. Drugs 2004 4 : 361 368.
42. Dasu MR, Riosvelasco AC, Jialal I. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 2009 202 : 76 83.
43. Ridker PM, Danielson E, Rifai N, for the Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension 2006 48 : 73 9.
44. Andersen S, Schalkwijk CG, Stehouwer CD, Parving HH. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care 2000 23 : 1031 1032.
45. Prasad A, Koh KK, Schenke WH et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am. Heart J. 2001 142 : 248 253.
46. 1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology 2004 55 : 195 203.
47. Del Fiorentino A, Cianchetti S, Celi A, Dell'Omo G, Pedrinelli R. The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vasc. Health Risk Manag. 2009 5 : 233 242.
48. Schnabel RB, Lunetta KL, Larson MG et al. The relation of genetic and environmental factors to systemic inflammatory biomarker concentrations. Circ. Cardiovasc. Genet. 2009 2 : 229 237.